AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 291 min read$BIVI

Chappell Amy Suzon purchased $2K of BIVI

Chappell Amy Suzon purchased 727 shares of BIOVIE INC. (BIVI) at $2.16 on 2026-08-28.

Original reporting
SEC EDGAR · Chappell Amy Suzon
Published Aug 29, 2026, 1:01 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 29, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BIVI
Neutral
high confidence
Mentioned
$BIVI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BIVINeutralLow
01

Why it matters

The purchase is modest and unlikely to move the stock, but it adds to the insider activity record.

02

Market read

Limited relevance; primarily of interest to existing shareholders and insider‑tracking traders.

03

What to watch

Potential upcoming clinical data or partnership not disclosed yet.

Relevance 4/10Novelty 4/10Timing: same-day filing

Background

Form 4 filings disclose insider transactions; director purchases are monitored for signals of confidence.

Company-level read

Ticker impact

$BIVINeutralHigh confidence
Context

Director Amy Suzon purchased 727 shares of BIOVIE at $2.16 each, total $1,570, disclosed via Form 4 on 2026-08-28.

Expected impact

No material move; possible slight uptick if market perceives confidence.

Evidence & confidence

Purchase size is small relative to market cap and typical trading volume; director ownership remains minimal.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; company is US‑listed with limited market presence.

Global

Low; only relevant to BIVI shareholders.

Counterpoint

What could challenge this read

Even small insider buys can signal confidence; monitor for future purchases.

Key entities

  • Director
    Amy Suzon

    Director of BIOVIE who made the purchase.

  • Company
    BIOVIE Inc.

    Biotech firm listed under ticker BIVI.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BIVI insider trading history →

Related articles

AUG 7
$BIVIMedAI 8/10

BioVie stock sinks on Phase IIb Parkinson’s trial data

BioVie (NASDAQ: BIVI) shares fell after Phase IIb Parkinson’s trial data. On Aug. 6 the stock opened 33.3% lower at $1.36, briefly down nearly 60% to $0.82, then closed at $1.35, down 33.8% from Aug. 5. The data were released alongside a filing for a stock offering at $1.33 per share.

yahoo.com4 min
AUG 6
$BIVIMedAI 8/10

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

BioVie Inc (NASDAQ:BIVI) reported positive Phase 2 SUNRISE-PD results for its Parkinson's candidate bezisterim. The drug met prespecified endpoints in early-stage, untreated patients, improving blood inflammatory markers and EPNIC-15 versus placebo. Benefits were strongest in patients with higher baseline platelet counts. Safety was similar to placebo, with 39.3% adverse events vs 51.7%.

proactiveinvestors.com4 min
MAY 30
$BIVIMedAI 9/10

BioVie: Long COVID trial fully enrolled – ICYMI

BioVie Inc (NASDAQ:BIVI) said its Phase 2 long COVID trial of bezisterim is fully enrolled, with more than 200 patients randomized to placebo or bezisterim. CEO Cuong Do said the study includes sites such as Yale, Mount Sinai, Mayo Clinic and Stanford, targeting symptoms like brain fog, malaise and fatigue. Top-line results are expected by late October or as early as September; the company plans FDA discussions on accelerated approval or EUA if data support benefit-risk.

proactiveinvestors.com4 min